These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 31182535

  • 1. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, Rybak MJ.
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
    [Abstract] [Full Text] [Related]

  • 2. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae.
    Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X, Zhu Y, Xu Y, Yang Q.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0010724. PubMed ID: 38712934
    [Abstract] [Full Text] [Related]

  • 3. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM, Domene Ochoa S, López-Causapé C, Luque S, Sorlí L, Campillo N, López Montesinos I, Padilla E, Prim N, Angulo-Brunet A, Grau S, Oliver A, Horcajada JP.
    Microbiol Spectr; 2021 Sep 03; 9(1):e0058521. PubMed ID: 34319141
    [Abstract] [Full Text] [Related]

  • 4. Synergistic antibacterial activity of ceftazidime-avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae.
    Tüzemen NÜ, Önal U, Merdan O, Akca B, Ener B, Özakın C, Akalın H.
    Sci Rep; 2024 Jul 30; 14(1):17567. PubMed ID: 39080317
    [Abstract] [Full Text] [Related]

  • 5. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
    Köle M, Sesli Çetin E, Şirin MC, Cicioğlu Arıdoğan B.
    Mikrobiyol Bul; 2022 Apr 30; 56(2):230-250. PubMed ID: 35477227
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Activity of Ceftazidime-Avibactam Alone and in Combination with Amikacin Against Colistin-Resistant Gram-Negative Pathogens.
    Chen T, Xu W, Yu K, Zeng W, Xu C, Cao J, Zhou T.
    Microb Drug Resist; 2021 Mar 30; 27(3):401-409. PubMed ID: 32721272
    [No Abstract] [Full Text] [Related]

  • 7. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2018 Jul 30; 62(7):. PubMed ID: 29914950
    [Abstract] [Full Text] [Related]

  • 8. Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Klebsiella pneumoniae ST11 is related to low mutation rates.
    Pariona JGM, Vásquez-Ponce F, Becerra J, Martins-Gonçalves T, Pariona EMM, Madueño FT, Esposito F, V de Lima A, Mello Sampaio JL, Galhardo RS, Lincopan N.
    Microbiol Spectr; 2024 Oct 03; 12(10):e0117324. PubMed ID: 39190636
    [Abstract] [Full Text] [Related]

  • 9. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
    Oliva A, Al Ismail D, Arcari G, Miele MC, Casali E, Sacco F, Volpicelli L, De Angelis M, Mascellino MT, Cancelli F, Raponi G, Carattoli A, Venditti M.
    J Glob Antimicrob Resist; 2023 Jun 03; 33():321-327. PubMed ID: 37086891
    [Abstract] [Full Text] [Related]

  • 10. Resistance to ceftazidime-avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study.
    Valzano F, La Bella G, Lopizzo T, Curci A, Lupo L, Morelli E, Mosca A, Marangi M, Melfitano R, Rollo T, De Nittis R, Arena F.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0426623. PubMed ID: 38934607
    [Abstract] [Full Text] [Related]

  • 11. New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae.
    Yu W, Luo Q, Shen P, Chen Y, Xu H, Xiao Y, Qiu Y.
    Int J Antimicrob Agents; 2021 Dec 06; 58(6):106458. PubMed ID: 34706255
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.
    Sader HS, Carvalhaes CG, Streit JM, Doyle TB, Castanheira M.
    Microb Drug Resist; 2021 Mar 06; 27(3):342-349. PubMed ID: 32762605
    [Abstract] [Full Text] [Related]

  • 13. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of Pseudomonas aeruginosa.
    Mataraci Kara E, Yilmaz M, İstanbullu Tosun A, Özbek Çelik B.
    Infect Dis (Lond); 2020 Sep 06; 52(9):616-624. PubMed ID: 32427010
    [Abstract] [Full Text] [Related]

  • 14. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J, Paranos P, Georgiou PC, Vourli S, Antonopoulou S, Michelaki A, Vagiakou E, Pournaras S.
    Int J Antimicrob Agents; 2021 Nov 06; 58(5):106440. PubMed ID: 34551356
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
    Wang F, Zhou Q, Yang X, Bai Y, Cui J.
    PLoS One; 2021 Nov 06; 16(10):e0258426. PubMed ID: 34648556
    [Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae.
    Zhang W, Guo Y, Li J, Zhang Y, Yang Y, Dong D, Zhu D, He P, Hu F.
    Antimicrob Resist Infect Control; 2018 Nov 06; 7():142. PubMed ID: 30479755
    [Abstract] [Full Text] [Related]

  • 17. Emergence of ceftazidime-avibactam resistance in blaKPC-33-harbouring ST11 Klebsiella pneumoniae in a paediatric patient.
    Zhou J, Yan G, Tang C, Liu J, Fu P, Ding L, Yang W, Guo Y, Wang C, Lu G, Hu F.
    Int J Antimicrob Agents; 2024 Jun 06; 63(6):107163. PubMed ID: 38570018
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O.
    Antimicrob Agents Chemother; 2014 Jun 06; 58(3):1757-62. PubMed ID: 24395223
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G, Boattini M, Comini S, Iannaccone M, Bondi A, Cavallo R, Costa C.
    Eur J Clin Microbiol Infect Dis; 2022 Jan 06; 41(1):63-70. PubMed ID: 34462816
    [Abstract] [Full Text] [Related]

  • 20. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    Zheng M, Li FH, Liu J, Li WJ, Yin RX, Cai DT, Andrey DO, Zheng SL, Gales AC, Zhang WJ, Sun J, Liao XP, Yu Y.
    J Antimicrob Chemother; 2024 May 02; 79(5):1069-1080. PubMed ID: 38526879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.